This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
12 Aug 2014

HPAPIs and Cytotoxic Drugs Manufacturing Market to Evolve Rapidly

Roots Analysis has announced the addition of “HPAPIs and Cytotoxic Drugs Manufacturing Market” report to their portfolio. The report provides an extensive study of the contract manufacturing opportunity for this rapidly expanding market. It identifies various CMOs active in this space, their capabilities with respect to manufacturing of HPAPIs and cytotoxic drugs, scale of operation (laboratory/development/commercial), occupational exposure limits (OELs) and geographic location/spread of the facilities. The focus of this report is primarily to understand the likely future evolution of HPAPIs and cytotoxics over the next decade.



Shefali Asija, the principal analyst, said: “Due to their numerous advantages and increased applications in treatment of cancer and other disorders, HPAPIs and cytotoxics have emerged as one of the key focus areas of researchers and manufacturers across the globe. Despite the fact that production of HPAPIs and cytotoxic drugs require specialised containment requirements making it a capital extensive business, a lot of CMOs are involved actively in the market.”



The report examines insights gathered from interviews of important stakeholders such as Corden Pharma, Helsinn, Catalent Pharma Solutions and Piramal Healthcare. Asija further stated: “Majority of our work is supported by detailed research. For the purposes of this report, we studied close to 60 investment programmes which have taken place since 2004. The success of the market lies in the increasing number of collaborations between contract manufacturers and pharmaceutical companies.” The firm had previously done a focused study on ADC contract manufacturing market.

Key topics covered in the latest report are
• Analysis of contract manufacturers involved in HPAPIs and cytotoxics manufacturing
• Pharmaceutical companies with in-house manufacturing
• Future market evolution
• Recent deals and partnerships
• Investment programs
• Regulatory landscape
• Special focus on ADC contract manufacturing
• Profiles of leading companies
• Case studies on companies providing ‘one stop shop’ service.

Related News